It's a big market and DXB already has signed licensing deals with 3 pharmas. I would imagine that if they pull out because they want to change to filspari, there would be big compensation payments to DXB. Apart from that, DMX-200 may perform on eGFR (which filspari didn't) and may perform as well or better on proteinuria. As well, DMX200 has a better safety profile. I like the odds but we will not know until August.
As well, there is no guarantee that Travere's application will be accepted. They have to wait 60 days for that. And if their application is accepted, there are no guarantees that filspari will be approved for FSGS, despite PARASOL.
DXB Price at posting:
48.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)